ASLN
Income statement / Annual
Last year (2023), ASLAN Pharmaceuticals Limited's total revenue was $12.00 M,
and the percentage change from the previous year is not available.
In 2023, ASLAN Pharmaceuticals Limited's net income was -$44.22 M.
See ASLAN Pharmaceuticals Limited,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$12.00 M |
$0.00 |
$0.00 |
$0.00 |
$3.00 M |
$0.00 |
$0.00 |
$11.49 M |
$0.00 |
$0.00 |
Cost of Revenue |
$348,498.00
|
$331,752.00
|
$282,224.00
|
$297,758.00
|
$407,259.00
|
$241,556.00
|
$209,087.00
|
$124,370.00
|
$52,087.00
|
$0.00
|
Gross Profit |
$11.65 M
|
-$331,752.00
|
-$282,224.00
|
-$297,758.00
|
$2.59 M
|
-$241,556.00
|
-$209,087.00
|
$11.36 M
|
-$52,087.00
|
$0.00
|
Gross Profit Ratio |
0.97
|
0
|
0
|
0
|
0.86
|
0
|
0
|
0.99
|
0
|
0
|
Research and Development Expenses |
$42.50 M
|
$38.00 M
|
$22.02 M
|
$9.31 M
|
$16.59 M
|
$31.83 M
|
$30.62 M
|
$13.10 M
|
$6.22 M
|
$4.50 M
|
General & Administrative Expenses |
$13.24 M
|
$9.88 M
|
$11.83 M
|
$7.17 M
|
$8.51 M
|
$10.51 M
|
$9.33 M
|
$6.92 M
|
$6.61 M
|
$2.82 M
|
Selling & Marketing Expenses |
-$348,498.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$12.89 M
|
$9.88 M
|
$11.83 M
|
$7.17 M
|
$8.51 M
|
$10.51 M
|
$9.33 M
|
$6.92 M
|
$6.61 M
|
$2.82 M
|
Other Expenses |
-$11,127.00
|
$356,555.00
|
$2.21 M
|
$758,747.00
|
$23.07 M
|
$244,589.00
|
-$235.83
|
-$0.00
|
-$40,333.48
|
$5,456.42
|
Operating Expenses |
$55.39 M
|
$47.88 M
|
$33.85 M
|
$16.48 M
|
$48.17 M
|
$42.35 M
|
$39.94 M
|
$20.02 M
|
$12.84 M
|
$7.31 M
|
Cost And Expenses |
$55.74 M
|
$47.88 M
|
$33.85 M
|
$16.48 M
|
$48.58 M
|
$42.35 M
|
$39.94 M
|
$20.14 M
|
$12.84 M
|
$7.31 M
|
Interest Income |
$404,981.00
|
$354,457.00
|
$219.00
|
$592.00
|
$150,610.00
|
$268,330.00
|
$370,589.00
|
$0.00
|
$0.00
|
$0.00
|
Interest Expense |
$4.33 M
|
$3.68 M
|
$1.86 M
|
$1.25 M
|
$901,612.00
|
$491,904.00
|
$425,268.00
|
$521,505.00
|
$986,928.00
|
$295,403.00
|
Depreciation & Amortization |
$348,498.00
|
$331,752.00
|
$282,224.00
|
$297,758.00
|
$444,412.00
|
$241,556.00
|
$209,087.00
|
$75,998.00
|
$48,908.00
|
$24,853.00
|
EBITDA |
-$43.39 M |
-$47.61 M |
-$32.04 M |
-$15.72 M |
-$45.76 M |
-$41.44 M |
-$40.07 M |
-$8.41 M |
-$12.29 M |
-$7.04 M |
EBITDA Ratio |
-3.62
|
0
|
0
|
0
|
-15.25
|
0
|
0
|
-0.73
|
0
|
0
|
Operating Income Ratio |
-3.64
|
0
|
0
|
0
|
-15.19
|
0
|
0
|
-0.75
|
0
|
0
|
Total Other Income/Expenses Net |
-$342,753.00
|
-$2.97 M
|
$2.26 M
|
-$487,992.00
|
-$986,276.00
|
$176,913.00
|
-$767,727.68
|
-$289,500.68
|
-$1.14 M
|
-$49,517.80
|
Income Before Tax |
-$44.08 M
|
-$51.28 M
|
-$31.59 M
|
-$16.97 M
|
-$46.66 M
|
-$42.17 M
|
-$40.71 M
|
-$9.00 M
|
-$13.33 M
|
-$7.36 M
|
Income Before Tax Ratio |
-3.67
|
0
|
0
|
0
|
-15.55
|
0
|
0
|
-0.78
|
0
|
0
|
Income Tax Expense |
$132,667.00
|
$99,221.00
|
$3.12 M
|
$934,921.00
|
$408,002.00
|
$14,439.00
|
-$342,458.83
|
$173,835.00
|
$500,028.00
|
$245,885.00
|
Net Income |
-$44.22 M
|
-$51.38 M
|
-$34.71 M
|
-$17.91 M
|
-$47.07 M
|
-$42.19 M
|
-$40.71 M
|
-$9.00 M
|
-$13.33 M
|
-$7.36 M
|
Net Income Ratio |
-3.68
|
0
|
0
|
0
|
-15.69
|
0
|
0
|
-0.78
|
0
|
0
|
EPS |
-2.69 |
-3.68 |
-2.66 |
-2.33 |
-7.25 |
-7.04 |
-8.18 |
-1.73 |
-6.05 |
-28.81 |
EPS Diluted |
-2.69 |
-3.68 |
-2.66 |
-2.33 |
-7.25 |
-7.04 |
-7.82 |
-1.73 |
-6.05 |
-28.81 |
Weighted Average Shares Out |
$16.45 M
|
$13.95 M
|
$13.03 M
|
$7.69 M
|
$6.50 M
|
$5.99 M
|
$4.98 M
|
$5.20 M
|
$2.20 M
|
$255,588.00
|
Weighted Average Shares Out Diluted |
$16.45 M
|
$13.95 M
|
$13.03 M
|
$7.69 M
|
$6.50 M
|
$5.99 M
|
$5.20 M
|
$5.20 M
|
$2.20 M
|
$255,588.00
|
Link |
|
|
|
|
|
|
|
|
|
|